A team of researchers from the Massachusetts General Hospital have developed a novel fluorescence-based assay for sensitive detection of antibodies within microliter volume serum samples. This new assay is at least 50 times more sensitive than the traditional radioimmunoassay (RIA), which is the gold standard currently used in the clinic.
This new technology is particularly attractive for immunological assays as it allows use of very small volumes of sample reagents (5 ¦ÌL), and use of traditional analytical systems such as a standard real time PCR requires much lower sample volumes than traditional ELISA methods allowing the modular bead-based assay to be modified for use in studies using small animal models, where the sample volume can be a limiting factor.
The increased sensitivity of the assay could enable a more accurate determination of the onset of disease, as well as a better temporal resolution of disease progression.
The team have produced a combination of the several existing techniques, the result of which is a more sensitive, non-radioactive, clinically-relevant assay. It is hoped that this technique will become a useful tool for early detection of Islet Cell Autoantibodies (ICA) in at risk patients, which could lead to intervention before significant loss of islet cell mass.
This method is partially built on the sensitivity of Rolling Circle Amplification (RCA), and is designed around a modular assay so that it can be applied to any other antigen-antibody pair without the need for much modification. The researchers have demonstrated superior detection capability of two different autoantibodies, but this is by no means the end of the story as the assay can be easily adapted to include as many autoantibodies as possible.
The team plans to enhance this technology with a variety of engineering modifications, including multiplexing the assay for simultaneous detection of multiple antigens or antibodies within very small sample volumes.
Source: World Scientific Publishing Co.
Michelle Petersen is the founder of Healthinnovations, having worked in the health and science industry for over 21 years, which includes tenure within the NHS and Oxford University. Healthinnovations is a publication that has reported on, influenced, and researched current and future innovations in health for the past decade.
Michelle has been picked up as an expert writer for Informa publisher’s Clinical Trials community, as well as being listed as a blog source by the world’s leading medical journals, including the acclaimed Nature-Springer journal series.
Healthinnovations is currently indexed by the trusted Altmetric and PlumX metrics systems, respectively, as a blog source for published research globally. Healthinnovations is also featured in the world-renowned BioPortfolio, BioPortfolio.com, the life science, pharmaceutical and healthcare portal.
Most recently the Texas A&M University covered The Top 10 Healthinnovations series on their site with distinguished Professor Stephen Maren calling the inclusion of himself and his team on the list a reflection of “the hard work and dedication of my students and trainees”.
Michelle Petersen’s copy was used in the highly successful marketing campaign for the mega-hit film ‘Jumanji: The Next Level, starring Jack Black, Karen Gilian, Kevin Hart and Dwayne ‘The Rock’ Johnson. Michelle Petersen’s copywriting was part of the film’s coverage by the Republic TV network. Republic TV is the most-watched English language TV channel in India since its inception in 2017.
An avid campaigner in the fight against child sex abuse and trafficking, Michelle is a passionate humanist striving for a better quality of life for all humans by helping to provide traction for new technologies and techniques within healthcare.